恩替卡韦、丹参联合螺内酯治疗乙肝后肝硬化腹水的临床效果  

Clinical effect of entecavir,salvia miltiorrhiza combined with spironolactone in the treatment of ascites due to hepatitis B cirrhosis

作　　者：丁月丹 DING Yue-dan(Second People's Hospital of Benxi Manchu Autonomous County,Benxi 117108,China)

机构地区：[1]辽宁省本溪市本溪满族自治县第二人民医院,117108

出　　处：《中国实用医药》2022年第21期129-131,共3页China Practical Medicine

摘　　要：目的研究恩替卡韦、丹参联合螺内酯治疗乙型肝炎(乙肝)后肝硬化腹水的临床效果。方法96例乙肝后肝硬化腹水患者,随机分为对照组(49例)及观察组(47例)。对照组在常规治疗的基础上采用恩替卡韦治疗,观察组在常规治疗的基础上采用恩替卡韦、丹参联合螺内酯治疗。比较两组患者的临床疗效,治疗前后的肝功能指标[总胆红素(TBiL)、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)]水平,不良反应发生率。结果观察组患者的临床疗效优于对照组,差异有统计学意义(Z=3.6206,P=0.0003<0.05)。治疗前,两组患者的TBiL、AST、ALT水平比较,差异均无统计学意义(P>0.05);治疗后,两组患者的TBiL、AST、ALT水平均较本组治疗前降低,且观察组患者的TBiL(20.13±2.06)μmol/L、AST(40.06±4.93)U/L、ALT(30.04±3.15)U/L均低于对照组的(28.64±2.61)μmol/L、(49.54±5.13)U/L、(39.63±3.26)U/L,差异均具有统计学意义(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用恩替卡韦、丹参联合螺内酯治疗乙肝后肝硬化腹水,可在安全用药的前提下提升临床疗效,改善患者的肝功能,值得推荐。Objective To study the clinical effect of entecavir,salvia miltiorrhiza combined with spironolactone in the treatment of ascites due tohepatitis B cirrhosis.Methods A total of 96 patients with ascites due to hepatitis B cirrhosis were randomly divided into control group(49 cases)and observation group(47 cases).The control group was treated with entecavir on the basis of conventional treatment,and the observation group was treated with entecavir,salvia miltiorrhiza combined with spironolactone on the basis of conventional treatment.The clinical efficacy,liver function indexes[total bilirubin(TBiL),aspartate aminotransferase(AST),alanine aminotransferase(ALT)]levels before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results The clinical efficacy of the observation group was better than that of the control group,and the difference was statistically significant(Z=3.6206,P=0.0003<0.05).Before treatment,there was no statistically significant difference in the levels of TBiL,AST and ALT between the two groups(P>0.05).After treatment,the levels of TBiL,AST,and ALT in the two groups were lower than those before treatment in this group;the TBiL(20.13±2.06)μmol/L,AST(40.06±4.93)U/L,ALT(30.04±3.15)U/L in the observation group were lower than(28.64±2.61)μmol/L,(49.54±5.13)U/L,(39.63±3.26)U/L in the control group;the differences were all statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Entecavir,salvia miltiorrhiza combined with spironolactone in the treatment of ascites due to hepatitis B cirrhosis can improve the clinical efficacy and liver function of patients under the premise of safe medication,which is worthy of recommendation.

关 键 词：恩替卡韦 丹参 螺内酯 乙型肝炎 肝硬化 腹水 肝功能 疗效 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]